Second Quarter Results Total revenues of $36.5 million, a 23% year-over-year improvementNet income of $0.9 million and diluted earnings per share of $0.34, which includes a positive impact of $1.4 million related to the release of our deferred tax valuation allowance in CanadaAdjusted EBITDA of $2.2 million, a $1.3 million year-over-year improvement $25.4 million in cash and $7.7 million of total debt as of June 30, 2025 HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (Nasdaq: NCSM) ...

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. T ...

文章核心观点 公司2025年第二季度运营成果出色，各业务板块销售和盈利均有增长，基于良好表现上调全年业绩指引 [1][5] 各部分总结 第二季度业绩 - 综合净销售额达60亿美元，增长11.1%，按固定汇率计算增长10.3%，有机净销售额增长10.2% [2] - 医疗外科和神经科技业务净销售额38亿美元，增长17.3%，按固定汇率计算增长16.7%，有机净销售额增长11.0% [2] - 骨科业务净销售额22亿美元，增长2.0%，按固定汇率计算增长1.1%，排除脊柱植入业务剥离影响，增长10.7%和9.7%，有机净销售额增长9.0% [3] - 报告净收益8.84亿美元，增长7.2%，摊薄后每股净收益2.29美元，增长7.0% [4] - 报告毛利率63.8%，营业利润率18.5%，调整后毛利率65.4%，营业利润率25.7%，调整后净收益12亿美元，增长11.6%，摊薄后每股净收益3.13美元，增长11.4% [4] 2025年展望 - 上调全年指引，预计有机净销售额增长9.5% - 10.0%，调整后摊薄每股净收益13.40 - 13.60美元 [5] - 销售指引含适度有利定价影响，外汇若维持当前水平，对销售和调整后每股净收益有轻微积极影响 [6] - 预计2025年关税净影响约1.75亿美元 [7] 非GAAP财务指标 - 公司补充非GAAP财务指标，包括固定汇率销售增长百分比、有机销售增长百分比等，认为这些指标有助于投资者理解财务结果和评估未来业绩 [29] - 计算固定汇率销售增长百分比需消除外汇汇率变化影响，计算有机销售增长百分比需消除外汇汇率、收购和剥离影响，计算收益表现需排除影响运营结果可比性和收益趋势的特定项目 [30] 销售增长分析 - 按地域，美国销售额45.54亿美元，增长12.5%，国际销售额14.68亿美元，增长6.8% [25] - 按业务板块，医疗外科和神经科技业务销售额37.71亿美元，增长17.3%，骨科业务销售额22.51亿美元，增长2.0% [25] 补充销售增长分析 - 医疗外科和神经科技业务各细分领域有不同程度增长，如血管业务增长52.3% [27] - 骨科业务各细分领域也有增长，如创伤和四肢业务增长15.0% [27] 非GAAP与GAAP财务指标调节 - 详细列出了各项调整项目对GAAP财务指标的影响，如收购和整合相关成本、无形资产摊销等 [33][34][35]

SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, after the market closes. A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event. About ZoomZoom’s mission is t ...

WESTBROOK, Maine, July 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it plans to release financial results for the second quarter ended June 30, 2025, on Thursday, August 14, 2025, before the open of market trading. In conjunction with reporting second quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company’s Chief Executive Officer, Jack R ...

Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the Phase 3 Aspire study evaluating GTX-102 (apazunersen) as a treatment for Angelman Syndrome is fully enrolled, with approximately 129 participants ages four to 17 with a genetically confirmed diagnosis of full m ...

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Partici ...

Raises Full-year GuidanceCHARLOTTE, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- SPX Technologies, Inc. (NYSE:SPXC) (“SPX”, the “Company”, “we” or “our”) today reported results for the second quarter ended June 28, 2025. Second Quarter Highlights (amounts presented for continuing operations; all comparisons against the second quarter of 2024, unless otherwise noted) Revenue of $552.4 million, up 10.2%GAAP income from continuing operations of $52.5 million, up 16.2%GAAP EPS of $1.10, up 14.6%Adjusted EPS* of $1.6 ...

公司动态 - 公司将于2025年8月14日美国东部时间上午10:00举行电话会议，讨论截至2025年6月30日的第二季度业绩 [1] - 电话会议将通过公司官网Sowginc.com进行直播并提供回放 [3] - 参会者需通过指定链接注册获取拨入信息，如有技术问题可联系Gateway Group [2] 公司介绍 - 公司是美国领先的冻干糖果和零食制造商，专注于提供创新且风味独特的冻干糖果 [4] - 公司拥有专有冻干技术和专业生产设施，将传统糖果转化为新型冻干糖果品类 [4] - 公司发展核心支柱包括创新、可扩展性、卓越制造、有意义的就业机会和食品质量标准 [4] 联系方式 - 投资者关系联系人Cody Slach，电话1-949-574-3860，邮箱SOWG@gateway-grp.com [5] - 媒体联系人电话1-214-623-6055，邮箱pr@sowginc.com [5]

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s ...